Skip to content

Kefazolin Versus Kefazolin Plus Metronidazole to Reduce Postpartum Infection

Randomised Trial Comparing Pre-operative Administration of Single Dose Kefazolin to Kefazolin Plus Metronidazole to Reduce Postpartum Infection

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04792710
Enrollment
1000
Registered
2021-03-11
Start date
2021-03-08
Completion date
2022-06-30
Last updated
2021-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of Postpartum Sepsis

Brief summary

Randomised controlled trial to investigate the efficacy of adding metronidazole pre-operatively to kefazolin in reducing postpartum infection

Detailed description

All pregnant patients scheduled for emergency or elective Caesarean section ≥18 years, willing and able to provide informed consent and not receiving antibiotics, will be eligible for recruitment. Patients will be randomised into receiving kefazolin according to current standard of care administered pre-operatively intravenously with placebo (control arm), and kefazolin according to current standard of care administered pre-operatively with metronidazole 500 mg intravenously pre-operatively. Outcome measures will be surgical site infection, urinary tract infection and postpartum endometritis. Five hundred patients will be recruited in each arm

Interventions

DRUGMetronidazole

Metronidazole 500 mg intravenous stat dose prior to skin incision

Sponsors

University of Pretoria
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Masking description

The out comes assessor will not have access to the arm the patient was randomised to.

Intervention model description

Randomised placebo controlled trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

18 years and older Willing and able to provide written informed consent

Exclusion criteria

* women younger than 18 years women not able or willing to provide written informed consent women with or without infection already receiving antibiotics for other indications women allergic to kefazolin or metronidazole

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of reducing surgical site infectionSeven days post-operativelyIncidence of surgical site infections

Secondary

MeasureTime frameDescription
Efficacy of reducing urinary tact infectionsThree days post-operativelyIncidence of urinary tract infections
Efficacy of reducing postpartum endometritisSeven days post-operativelyIncidence of endometritis

Countries

South Africa

Contacts

Primary ContactLeon C Snyman, PhD
leon.snyman@up.ac.za+27834621818
Backup ContactLouisa Seopela, MMed (O&G)
drseopela@yahoo.com+27833014790

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026